NEW YORK, Oct. 2 – Canadian proteomics company Interomex BioPharmaceuticals said Tuesday it raised $6.3 million Canadian ($4.0 million) in a second round of private financing.

Interomex BioPharmaceuticals of Vancouver said that the Business Development Bank of Canada led the round, which also included contributions from new investors, Ventures West and T2C2 of Montreal. Existing investors GeneChem Technologies Venture Fund and Western Technology Seed Investment Fund also participated in the round.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.